Q4 Earnings Estimate for COLL Issued By HC Wainwright

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at HC Wainwright issued their Q4 2026 EPS estimates for Collegium Pharmaceutical in a report issued on Friday, January 9th. HC Wainwright analyst B. Folkes anticipates that the specialty pharmaceutical company will post earnings of $1.66 per share for the quarter. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The business had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%.

A number of other research analysts also recently weighed in on COLL. Barclays reduced their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday. Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a research note on Wednesday. Needham & Company LLC raised their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $52.80.

Collegium Pharmaceutical Price Performance

COLL stock opened at $45.54 on Monday. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The company has a market cap of $1.44 billion, a P/E ratio of 28.29 and a beta of 0.60. The firm has a 50-day moving average of $46.23 and a 200 day moving average of $38.61. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27.

Insider Transactions at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 30,000 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 51,250 shares of company stock worth $2,235,352. Corporate insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. raised its holdings in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the last quarter. CWM LLC lifted its holdings in shares of Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Collegium Pharmaceutical by 368.9% in the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 2,169 shares during the period.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium issued 2026 financial guidance that topped consensus on revenue. Management expects product revenues of $805M–$825M (vs. consensus ~$782.9M) and adjusted EBITDA of $455M–$475M; Jornay PM net revenue is guided to $190M–$200M. This stronger-than-expected top‑line and profitability outlook is a clear positive catalyst. Collegium Provides 2026 Financial Guidance and Business Update
• Positive Sentiment: Needham raised its price target from $48 to $56 and maintained a “buy” rating, implying roughly 23% upside from the current level — a supportive analyst endorsement that can attract buyers. Benzinga TickerReport
• Neutral Sentiment: Barclays trimmed its price target slightly (from $58 to $56) but kept an “overweight” rating — a mixed signal that reduces upside expectations a bit while still indicating conviction in the name. Benzinga
• Neutral Sentiment: A broader industry piece highlighting branded pharmaceuticals and peer Q3 results mentions the group context for names like Collegium; useful for benchmarking but not specific company news. MSN: Branded pharmaceuticals stocks Q3 results
• Negative Sentiment: Zacks downgraded Collegium from “strong-buy” to “hold,” which may prompt some profit‑taking or limit fresh inflows from investors who follow Zacks ratings. Zacks TickerReport

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.